Skip to main content
RESMED INC logo

RESMED INC — Investor Relations & Filings

Ticker · RMD LEI · 254900O2VD7IQ5OGI615 ASX Manufacturing
Open in API
Filings indexed 1,641 across all filing types
Latest filing 2024-11-03 Regulatory Filings
Country AU Australia
Listing ASX RMD

About RESMED INC

https://www.resmed.com

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the management of sleep-disordered breathing, chronic obstructive pulmonary disease, and other respiratory conditions. The company’s primary product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel machines, and a variety of masks and accessories designed to improve patient adherence and comfort. ResMed distinguishes itself through its focus on digital health, offering integrated software platforms that enable remote patient monitoring and data-driven clinical insights for healthcare providers. Additionally, the company provides software-as-a-service (SaaS) solutions to support out-of-hospital care settings, including home health, hospice, and skilled nursing facilities, aiming to improve patient outcomes and reduce overall healthcare costs.

Recent filings

Filing Released Lang Actions
Statement of CDIs on issue - RMD 3 pages 12.4KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4A - Statement of CDIs on issue' and contains detailed information about the number and class of CHESS Depositary Interests (CDIs) and other securities on issue for ResMed Inc. It includes monthly statements of securities issued, net differences, reasons for changes such as transfers, stock options, employee stock purchase plans, and share repurchases. The document is a regulatory announcement related to securities issued and changes in share capital but does not contain financial statements, management discussion, or audit information. It is a formal regulatory filing to the ASX about securities on issue, consistent with Appendix 4A filings which are standard for reporting securities issued and changes. The document length is 3048 characters, relatively short and focused on securities issued rather than financial results or management commentary. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Share Issue/Capital Change (SHA) because it is a standard Appendix 4A statement rather than a new share issue announcement or capital change event.
2024-11-03 English
Form 10-Q for the Quarter Ended September 30, 2024 39 pages 474.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-Q' and explicitly states it is a 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934' for the quarterly period ended September 30, 2024. It contains detailed unaudited condensed consolidated financial statements including balance sheets, statements of operations, comprehensive income, changes in equity, and cash flows, as well as management's discussion and analysis. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the actual quarterly report, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2025
2024-10-27 English
Amendment to Notice of Annual Meeting/Proxy Form 2 pages 96.6KB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement related to the Annual Meeting of Stockholders. It is specifically labeled as an amendment to the proxy statement for the annual meeting. The content focuses on correcting contact information for voting and accessing the proxy statement and annual report, without presenting any financial data or detailed report content. The document is short (2235 characters) and serves as an amendment to previously filed proxy materials. According to the filing definitions, proxy statements and related materials fall under Proxy Solicitation & Information Statement (PSI). Therefore, the document is best classified as PSI.
2024-10-27 English
ResMed Announces Results for the First Quarter of FY2025 10 pages 149.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025' and contains detailed financial data including revenue, gross margin, income from operations, net income, earnings per share, and operating cash flow for the quarter ended September 30, 2024. It includes unaudited condensed consolidated statements of operations and balance sheets, as well as discussion of business highlights and dividend declarations. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a quarterly earnings report providing comprehensive financial results and analysis for a fiscal quarter. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2024-10-24 English
Dividend/Distribution - RMD 4 pages 15.8KB
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Appendix 3A.1 - Notification of dividend / distribution' and contains detailed information about a dividend payment, including the dividend amount, ex-date, record date, payment date, currency, and tax withholding rate. It specifically announces a dividend of USD 0.053 per share for holders of Chess Depositary Instruments (CDIs). The content is focused on the dividend announcement and payment details rather than financial results or reports. The document length is 4571 characters, which is relatively short and consistent with a dividend announcement rather than a full financial report. Therefore, this document fits the category of 'Notice of Dividend Amount' (DIV).
2024-10-24 English
Form 4 - Statement of Changes in Beneficial Ownership 2 pages 13.1KB
Director's Dealing Classification · 100% confidence The document is a Form 4 filed with the U.S. Securities and Exchange Commission (SEC), which reports changes in beneficial ownership of company securities by insiders such as officers, directors, or significant shareholders. It includes detailed tables of securities acquired or disposed of, transaction dates, prices, and ownership forms. The presence of terms like 'Section 16(a) of the Securities Exchange Act of 1934', 'Statement of Changes in Beneficial Ownership', and the format of the document clearly identify it as a Director's Dealing report. It is not an earnings release, annual report, or any other type of financial or regulatory filing. Therefore, the correct classification is Director's Dealing (DIRS).
2024-10-16 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.